SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after a significant drop following mixed Phase 3 trial results, specifically related to high placebo response impacting statistical significance. The conversation centers on whether the sell-off is an overreaction given the company's cash reserves and ongoing pipeline, with some speculating about a potential buyout and others wary of the mixed data. Community members are actively discussing dip-buying strategies, potential bounce-back scenarios, and comparisons to competitor performance.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following news of a partnership with Google to enhance AI-powered shopping experiences. While some investors are excited about the potential growth, others express frustration with the stock's historical underperformance and question whether the partnership will provide an immediate catalyst. Community members are debating whether this is a turning point or another false start for the fintech giant.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp drop in stock price following remarks made by a former FDA official, George Tidmarsh, regarding the drug Voclosporin. The community is expressing concerns about the validity and timing of the statement, with some suspecting market manipulation and questioning the company's leadership response. The drop has also impacted buyout hopes.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Shares of Robinhood are trending as the stock rallies to new all-time highs, fueled by optimism around its S&P 500 inclusion and growth in its prediction markets business; the community is closely watching for continued momentum. Several analysts have recently raised their price targets, with some traders speculating on further upside. The stock has become a favorite among millennial traders as it rides the crypto wave and wealth transfer megatrend.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending due to significant volume and breakout signals, attracting attention as a China pet play. The community is discussing potential parabolic moves and Elliott Wave patterns, with some mentioning the possibility of a short squeeze. It is also on a list of stocks hitting new 52-week highs sorted by volume.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members express excitement about its potential and discuss where to purchase it, touting it as a token for the culture. The crypto is also linked to broader discussions around cannabis legalization and the culture surrounding it. Community sentiment is highly bullish, with some suggesting it could be a safer investment than traditional weed stocks.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to a video posted by Trump discussing the medical benefits of CBD for seniors, sparking community discussion around potential rescheduling.  Traders are actively weighing the implications of potential policy changes and the sector's volatile nature, while some highlight positive movement in European cannabis markets. The community speculates on the timing and impact of any official announcements.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt Holdings is trending due to renewed interest following news of a new board appointment, sparking discussions about the company's potential growth strategy within the digital asset space. The community is actively speculating about the impact of new leadership and potential partnerships, especially regarding expansion into foreign markets and web3 technologies. Bullish sentiment is building around the possibility of a short squeeze and the company's strengthened financial position after debt reduction.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending following a strong earnings report, with revenue and GMV growth exceeding expectations. The community is discussing the company's resilience in the face of potential headwinds like tariffs, along with its expanding partnerships and AI initiatives. Bullish sentiment is fueled by raised price targets and the anticipation of continued growth, though some caution against overvaluation.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amid accusations from a short seller, Fuzzy Panda Research, causing significant price volatility and debate among investors. The community is actively discussing the validity of the short report, the company's response, and the potential impact on upcoming earnings, with many expressing confidence in Rezolve's long-term prospects due to its partnerships and recent capital raise. Despite the controversy, some traders are seeing a buying opportunity, while others remain cautious, awaiting further developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?

Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream 

Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum. 

INCY Announces New Late-Stage Data on Skin Disease Drug

Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth

ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.

Barclays has initiated coverage of Incyte (INCY) with an ‘Overweight’ rating and a $90 price target on Friday.The price target implies an over 20% upside to the stock’s closing price on Thursday.&nbsp;Shares of the company traded about 0.4% higher on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INCY">INCY</a> trended in the ‘bullish’ territory, accompanied by ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1332/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_2_26_04_PM_png_30d60d7ced.webp" alt="INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits" width="1332" height="126"><figcaption>INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits</figcaption></figure>The firm said that it sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.It believes the pivotal data for Tafasitamab in diffuse large B-cell lymphoma and the mid-stage data for Povorcitinib in chronic spontaneous urticaria patients provide the next legs of growth for Incyte.Earlier this week, Incyte said during its second-quarter earnings that it now expects late-stage data from the study evaluating Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma by the second half of 2025. Incyte is now focusing on its development pipeline as its cancer drug, Jakafi, nears patent expiration.“Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth,” CEO Bill Meury said.Jakafi net revenue came in at $764 million in the second quarter of the year, marking a growth of 8% year-on-year, and accounting for about 63% of the company’s total revenue in the quarter of $1.216 billion, which surpassed Wall Street expectations. &nbsp;For the full year, the company is eyeing revenue of $3 billion to $3.5 billion from Jakafi.Another important drug from the company is its Opzelura cream, used to treat nonsegmental vitiligo, which brought in revenues of $164 million in the second quarter, marking a growth of 35% year-on-year.Overall, for the second quarter, the company reported an adjusted and diluted earnings per share of $1.57, compared to a loss per share of $1.82 reported in the corresponding period of 2024.According to data from Koyfin, 11 of 27 analysts covering the stock rate it ‘Buy’ or higher, while 15 rate it ‘Hold’, and just one rates it a ‘Sell’. The average price target on the stock is $79.87, representing an upside of about 6% from the current price.The stock is up by over 9% this year and by about 17% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pheton-holdings-dismisses-rumors-of-acquisition-by-gilead/chrEENyRdRR">Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer 

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.

Equity

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.


Why Incyte (INCY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$1.61	--	--	N/A
Q2 '25	$1.40	$1.57	12.22%	BEAT
Q1 '25	$0.98	$1.16	18.55%	BEAT
Q4 '24	$1.46	$1.43	-2.16%	MISSED
Q3 '24	$0.98	$1.07	8.63%	BEAT

INCY
Incyte Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest INCY News

INCY Incyte Corp.